COMMUNIQUÉS West-GlobeNewswire

BeiGene Announces Clinical Results of Zanubrutinib in Mantle Cell Lymphoma From Two Presentations at the 60th American Society of Hematology Annual Meeting
01/12/2018
Company to Host Investor Meeting and Webcast on Monday, December 3, at 8 pm PST CAMBRIDGE, Mass. and BEIJING, China, Dec. 01, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage [...]
Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
01/12/2018
In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration of remission still not [...]
Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant
01/12/2018
Experience to date in clinical study shows high clinical response rates for patients with visceral GvHD or GvHD that was refractory to standard of care treatment SAN DIEGO, Dec. 01, 2018 (GLOBE NEWSWIRE) -- Bellicum [...]
Initial Data from Shire Collaboration Identifies Key Biomarkers That Affect Bleeding Patterns, Response to Treatment for Hemophilia A
01/12/2018
Initial Data from Shire Collaboration Identifies Key Biomarkers That Affect Bleeding Patterns, Response to Treatment for Hemophilia A Data from iPATH Collaboration to be presented at the American Society of Hematology's [...]
Catalyst Biosciences Announces Updated Positive Interim Data from Its Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors
01/12/2018
Results demonstrate efficacy of subcutaneous prophylaxis with MarzAA, Catalyst’s high potency engineered FVIIa Data presented at 60 th American Society of Hematology Annual Meeting & Exposition SOUTH SAN FRANCISCO, [...]
Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018
01/12/2018
Interim results suggest rivo-cel outcomes were comparable to a control study of transplants from matched unrelated donors, a requirement for product registration in Europe Company on track to report final results in [...]
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
01/12/2018
New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patients Crizanlizumab, a monthly infusion being investigated [...]
Oncology Venture: Notice to Convene Extraordinary General Meeting
01/12/2018
INDKALDELSE TIL EKSTRAORDINÆR GENERALFORSAMLING NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING KALLELSE TILL EXTRA BOLAGSSTÄMMA Der indkaldes herved til ekstraordinær generalforsamling i Oncology Venture A/S (" [...]
Financière de Tubize SA : Buy-back of own shares
01/12/2018
FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: Anne Sophie Pijcke, general manager, aspijcke@icloud.com Buy-back of own shares Regulated information 1 st December 2018 The board of directors [...]
Financière de Tubize SA : Rachat d'actions propres
01/12/2018
FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Bruxelles Contact: Anne Sophie Pijcke, aspijcke@icloud.com Rachat d'actions propres Information réglementée 1 er décembre 2018 Le Conseil d'administration de [...]
Cooper Hotel Receives ConventionSouth’s Annual Readers’ Choice Award
01/12/2018
Cooper Hotel recognized for commitment to professionalism, creativity and service DALLAS, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Cooper Hotel is honored to accept the ConventionSouth 2018 Readers’ Choice Award. This is the [...]
Canopy Growth and Canopy Rivers Announce Completion of TerrAscend Restructuring
01/12/2018
TORONTO, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (“ Canopy Growth ”) and Canopy Rivers Inc. (“ Canopy Rivers ”) (TSXV: RIV) are pleased to announce the closing of the [...]
Exergen Global’s Sensors Help Smisson-Cartledge Biomedical (SCB) Develop a Solution to Ensure Safe Blood Transfusions With Reliable, Accurate Temperature Measurement
01/12/2018
Exergen Global Joins with SCB to help it Conquer Complexity in Building Fluid Infusion Systems that Maintain Precise Temperatures of Blood Products WATERTOWN, Mass. and ZIJTAART, the Netherlands, Nov. 30, 2018 (GLOBE [...]
Altimmune Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01/12/2018
GAITHERSBURG, Md., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a clinical-stage immunotherapeutics company, granted equity awards on November 30, 2018, that were previously approved by the [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/12/2018
CAMBRIDGE, Mass., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2018, that were previously [...]
Tetra Bio-Pharma Closes Financing With Aphria Inc.
30/11/2018
With increased cash Tetra will ramp up Drug Development Activities ORLEANS, Ontario, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc (“ Tetra ” or “ TBP ”), (TSX VENTURE: TBP) (OTCQB: TBPMF), has closed a private [...]
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs
30/11/2018
Partners discuss efforts to accelerate precision medicine solutions at ASH 2018 HILDEN, Germany and GERMANTOWN, Md. and FORT MYERS, Fla., Nov. 30, 2018 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime [...]
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
30/11/2018
Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 29 November 2017 and on 7 September 2018, issued convertible loans with total nominal amount of MSEK 28 and MSEK 35.2 respectively. In total circa [...]
Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin
30/11/2018
Planned introduction of patient-friendly pen auto-injector in 2019 designed to increase comfort and convenience of treatment across the entire Akari subcutaneous program Second eculizumab-resistant patient with [...]

Pages